Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $9.5600 (-2.35%) ($9.4100 - $9.8700) on Wed. Sep. 18, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.48% (three month average) | RSI | 43 | Latest Price | $9.5600(-2.35%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.9% a day on average for past five trading days. | Market Behavior | Normal for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(60%) XBI(56%) IWO(55%) IWM(52%) IWC(50%) | Factors Impacting FOLD price | FOLD will decline at least -1.24% in a week (0% probabilities). VIXM(-32%) VXX(-19%) TLT(-14%) TIP(-1%) UNG(0%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.24% (StdDev 2.48%) | Hourly BBV | 0 () | Intraday Trend | -2.2% | | | |
|
Resistance Level | $9.78 | 5 Day Moving Average | $9.75(-1.95%) | 10 Day Moving Average | $9.7(-1.44%) | 20 Day Moving Average | $9.78(-2.25%) | To recent high | -27.8% | To recent low | 3.5% | Market Cap | $2.469b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |